roquinimex has been researched along with gusperimus* in 6 studies
1 review(s) available for roquinimex and gusperimus
| Article | Year |
|---|---|
New immunosuppressants: testing and development in animal models and the clinic: with special reference to DSG.
Topics: Animals; Disease Models, Animal; Graft Rejection; Graft Survival; Guanidines; Heart Transplantation; Hydroxyquinolines; Immunosuppressive Agents; Rats; Transplantation, Heterologous; Transplantation, Homologous | 1993 |
5 other study(ies) available for roquinimex and gusperimus
| Article | Year |
|---|---|
Azathioprine does not potentiate the immunosuppressive effect of 15-deoxyspergualin in rat heart allografting.
Topics: Adjuvants, Immunologic; Animals; Azathioprine; Drug Synergism; Graft Survival; Guanidines; Heart Transplantation; Hydroxyquinolines; Immunosuppressive Agents; Male; Rats; Rats, Inbred Strains; Rats, Inbred WKY; Time Factors; Transplantation, Homologous | 1994 |
15-deoxyspergualin effects in rat heart allograft transplantation--relation to dose, timing, and cyclosporine.
Topics: Animals; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Guanidines; Heart Transplantation; Hydroxyquinolines; Immunosuppressive Agents; Male; Rats; Rats, Inbred Strains; Transplantation, Homologous | 1993 |
15-Deoxyspergualin potentiates the immunosuppressive effect of cyclosporine A in a rat heart allograft model.
Topics: Adjuvants, Immunologic; Animals; Cyclosporine; Drug Synergism; Graft Survival; Guanidines; Heart Transplantation; Hydroxyquinolines; Immunosuppressive Agents; Male; Rats; Rats, Inbred Strains; Rats, Inbred WKY; Transplantation, Heterotopic; Transplantation, Homologous | 1993 |
Effect of LS-2616 on the graft protection achieved by cyclosporin A, prednisolone, and 15-deoxyspergualin in heart-transplanted rats.
The immunostimulator LS-2616 abolishes the effect of cyclosporin A in a rat cardiac transplantation model. The present paper compares the characteristics of rejection obtained under different immunosuppressive regimens with and without additional LS-2616 application in the same model. Cyclosporin A (CyA, 10 mg/kg daily), prednisolone (15 mg/kg daily), or 15-deoxyspergualin (2, 5, or 10 mg/kg daily), all given from the day of transplantation until day 9, protected the grafts during the treatment period. The addition of LS-2616 (160 mg/kg, day -1 until stop) resulted in a total abrogation of the immunosuppressive effect of CyA and prednisolone. However, LS-2616 could only partially or not at all reverse the effect of 15-deoxyspergualine. These results show a certain drug selectivity of LS-2616 in promoting rejection of immunosuppressed allografts. Further studies with LS-2616 may be of benefit in evaluating the mode of action of different immunosuppressive compounds and, thus, contribute to finding more effective antirejection therapies. Topics: Adjuvants, Immunologic; Animals; Cyclosporine; Graft Survival; Guanidines; Heart Transplantation; Hydroxyquinolines; Immunosuppressive Agents; Models, Animal; Prednisolone; Rats; Rats, Inbred Strains; Rats, Inbred WKY; Time Factors | 1992 |
Mode of action of immunosuppressive drugs evaluated with the aid of the immunostimulator LS-2616: studies on rejecting rat cardiac allografts.
Topics: Adjuvants, Immunologic; Animals; Cyclosporins; Drug Evaluation, Preclinical; Graft Rejection; Guanidines; Heart Transplantation; Hydroxyquinolines; Immunosuppressive Agents; Prednisolone; Rats; Rats, Inbred Strains; Transplantation, Homologous | 1992 |